Researchers are excitedly investigating retatrutide, a innovative medication developed by Eli Lilly, as a potential advance in body loss . Unlike many earlier approaches, retatrutide is a twin-action receptor targeting equally GLP-1 and GIP, substances that affect hunger and glucose control . Initia